Comparison of the Xpert breast cancer stratifier mRNA assay with central ER, PR, HER2, and Ki67 immunohistochemistry (IHC) for rapid biomarker analysis in developing countries

被引：0
|
作者：
Brock, J. E.
Milner, D. A.
Ho, K.
Natalie, W.
Victor, C.
Annaliza, R.
Teresa, B.
Kathryn, G-F
Edwin, L. W.
Jodi, W.
Wendy, W.
Michael, B.
机构：
[1] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA
[2] Cepheid, Sunnyvale, CA USA
来源：
CANCER RESEARCH | 2017年 / 77卷
关键词：
D O I：
10.1158/1538-7445.SABCS16-P2-05-07
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2-05-07
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Expression of ER, PR, HER2 and Ki67 in the neoadjuvant GeparX trial: Comparison of central immunohistochemistry with an automated cartridge-based system for mRNA assessment (on behalf of the GBG neoadjuvant and translational subboard)
    Denkert, C.
    Jank, P.
    Link, T.
    ANNALS OF ONCOLOGY, 2019, 30 : 8 - 9
  • [22] Conversion of ER, PR, HER2 and Ki-67 and Prognosis in breast cancer metastases to the brain
    Jiaxin, Chen
    Jinmei, Zhou
    Huiqiang, Zhang
    Xuexue, Wu
    Xiaobo, Wang
    Shaohua, Zhang
    Yanhong, Tai
    Zefei, Jiang
    Tao, Wang
    FRONTIERS IN NEUROLOGY, 2022, 13
  • [23] Reliability of preoperative core needle biopsy for determing ER, PR, HER2 status and Ki67 expression in invasive breast cancer
    Lakic, T.
    Ivkovic-Kapicl, T.
    Lovrenski, A.
    Sabo, J. Ilic
    Vuckovic-Hardi, L.
    Jelicic, I.
    VIRCHOWS ARCHIV, 2015, 467 : S52 - S52
  • [24] Effects of neoadjuvant trastuzumab, pertuzumab and palbociclib on Ki67 in HER2 and ER-positive breast cancer
    Luca Gianni
    Marco Colleoni
    Giancarlo Bisagni
    Mauro Mansutti
    Claudio Zamagni
    Lucia Del Mastro
    Stefania Zambelli
    Giampaolo Bianchini
    Antonio Frassoldati
    Ilaria Maffeis
    Pinuccia Valagussa
    Giuseppe Viale
    npj Breast Cancer, 8
  • [25] Effects of neoadjuvant trastuzumab, pertuzumab and palbociclib on Ki67 in HER2 and ER-positive breast cancer
    Gianni, Luca
    Colleoni, Marco
    Bisagni, Giancarlo
    Mansutti, Mauro
    Zamagni, Claudio
    Del Mastro, Lucia
    Zambelli, Stefania
    Bianchini, Giampaolo
    Frassoldati, Antonio
    Maffeis, Ilaria
    Valagussa, Pinuccia
    Viale, Giuseppe
    NPJ BREAST CANCER, 2022, 8 (01)
  • [26] Evaluation of ER, PgR, HER2 and Ki67 as predictors of response to neoadjuvant chemotherapy for operable breast cancer
    Burcombe, RJ
    Makris, A
    Richman, PI
    Pittam, M
    Daley, F
    Nobe, S
    Wilson, GD
    BRITISH JOURNAL OF CANCER, 2001, 85 : 50 - 50
  • [27] Change in ER, PR, HER2 status and Ki-67 after primary chemotherapy in breast cancer
    Petit, A.
    Loayza, C.
    Perez Casanova, L.
    Canellas, J.
    Falo, C.
    Perez, J.
    Soler, T.
    Climent, F.
    Gil, M.
    Pernas, S.
    Condom, E.
    VIRCHOWS ARCHIV, 2014, 465 : S124 - S125
  • [28] Europe-side external quality assessment (EQA) of RNA based testing of ER, PR, HER2 and Ki67 in invasive breast cancer
    Erber, R.
    Hartmann, A.
    Fasching, P.
    Stoehr, R.
    Beckmann, M. W.
    Zentgraf, M.
    Ruebner, M.
    Huebner, H.
    Fischer, J.
    Guerini Rocco, E.
    Viale, G.
    Cayre, A.
    Penault-Llorca, F.
    Caniego Casa, T.
    Palacios Calvo, J.
    Jank, P.
    Denkert, C.
    Khoury, L.
    Mairinger, T.
    Ferrazzi, F.
    ANNALS OF ONCOLOGY, 2020, 31 : S25 - S25
  • [29] Combined quantitative measures of ER, PR, HER2, and KI67 provide more prognostic information than categorical combinations in luminal breast cancer
    Abubakar, Mustapha
    Figueroa, Jonine
    Ali, H. Raza
    Blows, Fiona
    Lissowska, Jolanta
    Caldas, Carlos
    Easton, Douglas F.
    Sherman, Mark E.
    Garcia-Closas, Montserrat
    Dowsett, Mitch
    Pharoah, Paul D.
    MODERN PATHOLOGY, 2019, 32 (09) : 1244 - 1256
  • [30] Validation of the Xpert Breast Cancer STRAT 4 Assay on the GeneXpert instrument to Assess Hormone Receptor, Ki67, and HER2 Gene Expression Status in Breast Cancer Tissue Samples
    Sewanywa, Lina
    Hale, Martin
    Michelow, Pamela
    Mayne, Elizabeth
    Wiggill, Tracey
    APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2023, 31 (09) : 613 - 620
12345